Héctor Rodrigo-Lara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Héctor Rodrigo-Lara has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Rábano
Neuropathology Department, Reina Sofía Alzheimer Center, CIEN Foundation , ISCIII, 28031 Madrid
2 shared publications - Alicia Uceda-Heras
Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain
1 shared publication - Francisco Javier López González
Reina Sofia Alzheimer Center, CIEN Foundation, ISCIII, Madrid Spain
1 shared publication - Iago Rego-García
Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain
1 shared publication - Iván Burgueño-García
Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain
1 shared publication - Laura Saiz-Aúz
Alzheimer’s Disease Research Unit, CIEN Foundation, Queen Sofia Foundation Alzheimer Center, Madrid, Spain
1 shared publication
Latest Publications
- 29 October 2026
- Published by Oxford University Press (OUP) in Brain
The amygdaloid complex: from morphology to neurodegeneration
The amygdaloid complex is one of the most structurally and functionally heterogeneous regions of the mammalian brain, acting as an integrative node between sensory, mnemonic and visceral systems. It comprises a set of subnuclei whose cytoarchitectural differentiation, neurochemical profiles and anatomical boundaries have been debated since the earliest descriptions. This heterogeneity is established during ontogenetic development, assembling progenitors from pallial and subpallial domains, and preoptic and hypothalamic territories, resulting in a highly connected network. Maturation is not complete at birth, the amygdala changes through childhood and adolescence, leaving a protracted window of environmental sensitivity. Single-nucleus RNA sequencing and spatial transcriptomics have added a molecular layer to this framework, resolving populations that no single marker separates, and set explicit limits on the resolution at which rodent-derived subdivisions can be transferred to the human amygdala. Together these levels of description provide a structural framework for understanding its functions, which include emotional regulation and conditioned fear, social and sexual behaviours, decision-making, reward and punishment processing, empathy and memory modulation. Cross-species comparison reveals further variation, particularly the expansion of the basolateral complex in primates and the redistribution of neurons towards the lateral nucleus in humans. In summary, the amygdala acts as a densely connected hub with a broad role not only in physiological and psychological health but also in disease states; indeed, the amygdala is affected early in several neurodegenerative disorders, and in some (notably limbic-predominant age-related TDP-43 encephalopathy and argyrophilic grain disease) it is among the first regions in which pathology is detected.
- 29 October 2026
- Published by Oxford University Press (OUP) in Brain
The amygdaloid complex: from morphology to neurodegeneration
The amygdaloid complex is one of the most structurally and functionally heterogeneous regions of the mammalian brain, acting as an integrative node between sensory, mnemonic and visceral systems. It comprises a set of subnuclei whose cytoarchitectural differentiation, neurochemical profiles and anatomical boundaries have been debated since the earliest descriptions. This heterogeneity is established during ontogenetic development, assembling progenitors from pallial and subpallial domains, and preoptic and hypothalamic territories, resulting in a highly connected network. Maturation is not complete at birth, the amygdala changes through childhood and adolescence, leaving a protracted window of environmental sensitivity. Single-nucleus RNA sequencing and spatial transcriptomics have added a molecular layer to this framework, resolving populations that no single marker separates, and set explicit limits on the resolution at which rodent-derived subdivisions can be transferred to the human amygdala. Together these levels of description provide a structural framework for understanding its functions, which include emotional regulation and conditioned fear, social and sexual behaviours, decision-making, reward and punishment processing, empathy and memory modulation. Cross-species comparison reveals further variation, particularly the expansion of the basolateral complex in primates and the redistribution of neurons towards the lateral nucleus in humans. In summary, the amygdala acts as a densely connected hub with a broad role not only in physiological and psychological health but also in disease states; indeed, the amygdala is affected early in several neurodegenerative disorders, and in some (notably limbic-predominant age-related TDP-43 encephalopathy and argyrophilic grain disease) it is among the first regions in which pathology is detected.
- Open Access
- 10 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6755
Neuropathological Heterogeneity of Dementia Due to Combined Pathology in Aged Patients: Clinicopathological Findings in the Vallecas Alzheimer’s Reina Sofía Cohort
Background/Objectives: Clinicopathological research in late-life dementia has focused recently on combined neurodegenerative and vascular conditions underlying the high phenotypic heterogeneity of patients. The Vallecas Alzheimer’s Reina Sofía (VARS) cohort (n > 550), and particularly the series of associated brain donations (VARSpath cohort) are presented here. The aim of this study is to contribute to research in dementia with a well-characterized cohort from a single center. Methods: A total of 167 patients with complete neuropathological work-ups were analyzed here. The cohort is characterized by a high female predominance (79%), advanced age at death (88 yrs.), and a high frequency of ApoE-e4 haplotype (43%). Results: The main neuropathological diagnosis was Alzheimer’s disease (79.6%), followed by vascular dementia (10.2%) and Lewy body dementia (6%). Overall, intermediate-to-high cerebrovascular disease was observed in 38.9%, Lewy body pathology in 57.5%, LATE (TDP-43 pathology) in 70.7%, ARTAG in 53%, and argyrophilic grain disease in 12% of the patients. More than one pathology with a clinically relevant burden of disease was present in 71.1% of the brains, and a selection of premortem neuropsychological and functional scores showed significant correlation with the number of co-pathologies identified in postmortem brains. Conclusions: The VARS cohort, with thorough clinical follow-up, regular blood sampling, 3-Tesla MR, and a high rate of postmortem brain donation, can provide essential multidisciplinary data in the rising age of modifying therapies and biomarkers for Alzheimer’s disease and related dementias.
- 10 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6755
Open AccessNeuropathological Heterogeneity of Dementia Due to Combined Pathology in Aged Patients: Clinicopathological Findings in the Vallecas Alzheimer’s Reina Sofía Cohort
Background/Objectives: Clinicopathological research in late-life dementia has focused recently on combined neurodegenerative and vascular conditions underlying the high phenotypic heterogeneity of patients. The Vallecas Alzheimer’s Reina Sofía (VARS) cohort (n > 550), and particularly the series of associated brain donations (VARSpath cohort) are presented here. The aim of this study is to contribute to research in dementia with a well-characterized cohort from a single center. Methods: A total of 167 patients with complete neuropathological work-ups were analyzed here. The cohort is characterized by a high female predominance (79%), advanced age at death (88 yrs.), and a high frequency of ApoE-e4 haplotype (43%). Results: The main neuropathological diagnosis was Alzheimer’s disease (79.6%), followed by vascular dementia (10.2%) and Lewy body dementia (6%). Overall, intermediate-to-high cerebrovascular disease was observed in 38.9%, Lewy body pathology in 57.5%, LATE (TDP-43 pathology) in 70.7%, ARTAG in 53%, and argyrophilic grain disease in 12% of the patients. More than one pathology with a clinically relevant burden of disease was present in 71.1% of the brains, and a selection of premortem neuropsychological and functional scores showed significant correlation with the number of co-pathologies identified in postmortem brains. Conclusions: The VARS cohort, with thorough clinical follow-up, regular blood sampling, 3-Tesla MR, and a high rate of postmortem brain donation, can provide essential multidisciplinary data in the rising age of modifying therapies and biomarkers for Alzheimer’s disease and related dementias.